Quanterix Corporation (QTRX)
| Bid | 5.01 |
| Market Cap | 199.76M |
| Revenue (ttm) | 137.02M |
| Net Income (ttm) | -39.52M |
| EPS (ttm) | -1 |
| PE Ratio (ttm) | -5.15 |
| Forward PE | -5.12 |
| Analyst | Buy |
| Ask | 6 |
| Volume | 801,238 |
| Avg. Volume (20D) | 784,466 |
| Open | 5.30 |
| Previous Close | 5.16 |
| Day's Range | 5.05 - 5.30 |
| 52-Week Range | 4.67 - 19.18 |
| Beta | 1.35 |
About QTRX
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in variou...
Analyst Forecast
According to 4 analyst ratings, the average rating for QTRX stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 230.10% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · businesswire.com
Quanterix Releases Financial Results for the Fourth Quarter of 2024BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the f...
1 month ago · businesswire.com
Quanterix Highlights Compelling Benefits of Akoya Biosciences AcquisitionBILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX) (“Quanterix” or the “Company”), a company fueling scientific discovery through ultra-sensitive biomarker detection, today reiter...